Catalog11 refs
Hexarelin
Growth Hormone SecretagogueGrowth Hormone / IGF-1 AxistherapeuticMetabolicGrowth HormoneResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
MusclesSkin
Overview
Hexarelin (examorelin) is a synthetic hexapeptide growth hormone secretagogue that stimulates GH release through ghrelin receptors (GHSR-1a). It produces the most potent acute GH pulse among commonly studied GHRPs, including at doses where other secretagogues plateau. However, hexarelin's most distinctive feature is its significant cardioprotective activity, mediated through CD36 scavenger receptors on cardiac cells — an effect entirely independent of GH release. This dual pharmacology (GH secretagogue + cardioprotective agent) makes hexarelin unique in the GHRP class. The primary limitation is desensitization: GH response diminishes significantly after 4–8 weeks of continuous use, requiring cycling.
Primary Uses
Growth hormone release
Cardioprotection in ischemia models
Activation of ghrelin receptors for maximum GH secretion
muscle growth
anti aging
acute GH release
cardioprotection
ischemia-reperfusion protection
anti-atherogenic effects
cardiac remodeling
anti-inflammatory signaling
GH release studies
Cardioprotection research
Ghrelin-receptor pharmacology
Body-composition models
Ischemic acute kidney injury
Abdominal aortic aneurysm attenuation
Diabetes and diabetes-associated heart diseases
Acute lung injury (inflammation and fibrosis)
Attenuation of antinociceptive tolerance to morphine
GH Secretion
Synergy with GHRH
IGF-1 Elevation
Cardiomyocyte Protection
Calcium Channel Modulation
Fat Metabolism
Body Composition
Growth hormone research
Fat loss
Growth hormone release stimulation
Cardioprotection (preclinical)
Improved coronary flow
Protection against ischemia-reperfusion injury
Improved left ventricular function
Protocol Reference
Dose
100–200mcg per injection
Frequency
2-3 times daily
Half-life
Approximately 60-90 minutes
Route
Subcutaneous
Evidence
Phase 2 / Well Studied / Investigational - Clinical trials conducted; cardiovascular claims preclinical (disputed)
Research References· 21
Research Models
DogHumanMouseRatanimalsrodent
Also in Growth Hormone Secretagogue